https://viralytics.com/wp-content/u...om-the-Oncolytics-Virus-Pack-at-AACR-2017.pdf
"In our view, the MITCI trial update stole the show given the unmet need in melanoma patients who fail front-line checkpoint therapies. We reiterate our Buy rating and AUD$2 PT"
Will this move the market?
- Forums
- ASX - By Stock
- VLA
- Roth update on CAVATAK data presented at AACR
Roth update on CAVATAK data presented at AACR
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)